NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free KURA Stock Alerts $21.76 -0.30 (-1.36%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$21.26▼$22.2950-Day Range$17.53▼$22.9852-Week Range$7.41▼$24.17Volume937,600 shsAverage Volume1.14 million shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$27.94 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Kura Oncology alerts: Email Address Kura Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside28.4% Upside$27.94 Price TargetShort InterestBearish16.27% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.16Based on 3 Articles This WeekInsider TradingSelling Shares$57,922 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.56) to ($2.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector291st out of 903 stocksPharmaceutical Preparations Industry130th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKura Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Kura Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.27% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently decreased by 0.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 2.9 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 4 articles on an average week.Search Interest6 people have searched for KURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,922.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Kura Oncology is held by insiders.Read more about Kura Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to decrease in the coming year, from ($2.56) to ($2.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -10.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -10.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kura Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Kura Oncology Stock (NASDAQ:KURA)Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Stock News HeadlinesMay 21, 2024 | insidertrades.comKura Oncology, Inc. (NASDAQ:KURA) Insider Teresa Brophy Bair Sells 2,615 SharesJune 7 at 7:30 AM | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | globenewswire.comKura Oncology to Participate in Jefferies Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comKura Oncology, Inc. (KURA)May 19, 2024 | msn.comInvestor Enthusiasm Soars for Kura Oncology (NASDAQ:KURA)May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Positive Developments and Strong Trial ProgressMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic AdvantagesMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)May 14, 2024 | globenewswire.comKura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLMay 8, 2024 | globenewswire.comKura Oncology to Participate in Bank of America Securities Healthcare ConferenceMay 7, 2024 | seekingalpha.comKura Oncology: Balancing Act Of Promise And PragmatismMay 6, 2024 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | chron.comKura Oncology: Q1 Earnings SnapshotMay 3, 2024 | finance.yahoo.comKura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amid Strong Financials and Promising Clinical MilestonesMay 3, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | investorplace.comKURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024May 2, 2024 | msn.comKura Oncology Q1 2024 Earnings PreviewMay 2, 2024 | finance.yahoo.comKura Oncology Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comKura Oncology Reports First Quarter 2024 Financial ResultsApril 25, 2024 | globenewswire.comKura Oncology to Report First Quarter 2024 Financial ResultsApril 24, 2024 | uk.investing.comFDA grants breakthrough status for Kura Oncology's AML drug candicateApril 23, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLApril 22, 2024 | markets.businessinsider.comKura Oncology’s Buy Rating Affirmed by Analyst Joseph Pantginis Amid Breakthrough Therapy Designation and Promising Preclinical DataSee More Headlines Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/09/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees142Year FoundedN/APrice Target and Rating Average Stock Price Target$27.94 High Stock Price Target$37.00 Low Stock Price Target$10.50 Potential Upside/Downside+28.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.52% Return on Assets-34.11% Debt Debt-to-Equity Ratio0.02 Current Ratio16.67 Quick Ratio16.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book4.07Miscellaneous Outstanding Shares76,180,000Free Float71,991,000Market Cap$1.66 billion OptionableOptionable Beta0.94 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Chairman, CEO & President Comp: $1.22MMs. Kathleen Ford (Age 77)Chief Operating Officer Comp: $824.95kMs. Teresa Brophy Bair Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $705.38kDr. Stephen Dale M.D. (Age 52)Chief Medical Officer Comp: $855.3kMr. Thomas Doyle (Age 53)Senior Vice President of Finance & Accounting Mr. Pete De SpainExecutive Vice President of Investor Relations & Corporate CommunicationsDr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainMs. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementDr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentMr. Brian T. Powl M.B.A. (Age 50)M.S., Chief Commercial Officer More ExecutivesKey CompetitorsXencorNASDAQ:XNCRIronwood PharmaceuticalsNASDAQ:IRWDAimmune TherapeuticsNASDAQ:AIMTRa PharmaceuticalsNASDAQ:RARXZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsTeresa Brophy BairSold 2,615 sharesTotal: $57,922.25 ($22.15/share)Artal Group S.A.Bought 151,828 shares on 5/17/2024Ownership: 2.520%Alethea Capital Management LLCSold 90,839 shares on 5/17/2024Ownership: 0.341%Walleye Trading LLCBought 4,400 shares on 5/17/2024Ownership: 0.000%BVF Inc. ILSold 2,586,935 shares on 5/16/2024Ownership: 6.283%View All Insider TransactionsView All Institutional Transactions KURA Stock Analysis - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price target for 2024? 7 Wall Street analysts have issued 1-year price targets for Kura Oncology's stock. Their KURA share price targets range from $10.50 to $37.00. On average, they expect the company's stock price to reach $27.94 in the next twelve months. This suggests a possible upside of 28.4% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2024? Kura Oncology's stock was trading at $14.38 at the start of the year. Since then, KURA stock has increased by 51.3% and is now trading at $21.76. View the best growth stocks for 2024 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, May, 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.03. Kura Oncology's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.50) earnings per share. What ETFs hold Kura Oncology's stock? ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Range Cancer Therapeutics ETF (CNCR), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Loncar China Biopharma ETF (CHNA).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (6.28%), Vanguard Group Inc. (5.34%), Avoro Capital Advisors LLC (5.05%), Artal Group S.A. (2.52%), Affinity Asset Advisors LLC (0.96%) and Alethea Capital Management LLC (0.34%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KURA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.